To determine whether PGC1α is central to the disease improvements seen with NR supplementation during DSS colitis, we subjected Pgc1αΔIEC mice (mice lacking PGC1α within the intestinal epithelium) and their WT littermates (Pgc1αfl/fl) to DSS and treated them with either NR or vehicle via oral gavage. The gene discussed is PPARGC1A; the disease is colitis.